Magenta Therapeutics, Inc. (MGTA)
(Delayed Data from NSDQ)
$15.33 USD
+1.53 (11.09%)
Updated May 3, 2019 04:00 PM ET
After-Market: $15.30 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
MGTA 15.33 +1.53(11.09%)
Will MGTA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MGTA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MGTA
Take the Zacks Approach to Beat the Market: NVIDIA, Novo Nordisk, Magenta in Focus
The Zacks Analyst Blog Highlights Blue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta Therapeutics
MGTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Easing Banking Fears, Rate Hike Pause Boost Markets: 5 Picks
Magenta (MGTA) Down on Pipeline Update for Leukemia Drug
After Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)